Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 F276C||intrahepatic cholangiocarcinoma||predicted - sensitive||FGFR Inhibitor (Pan)||Infigratinib||Case Reports/Case Series||Actionable||In a Phase II trial, Truseltiq (infigratinib) treatment resulted in partial response after 2 months of therapy and response was maintained for 4 months in a patient with advanced intrahepatic cholangiocarcinoma harboring a FGFR2 F276C mutation, which is consistent with inhibition of Erk signaling in cholangiocarcinoma cells expressing FGFR2 F274C in culture (PMID: 30761385; NCT02150967).||30761385|
|FGFR2 F276C||intrahepatic cholangiocarcinoma||predicted - sensitive||FGFR2 Inhibitor||Pazopanib||Case Reports/Case Series||Actionable||In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that continued for 11 months after starting treatment in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 F276C (PMID: 34480077).||34480077|